Event Date:
05/13/2026
Time: 11:30 am - 1:00 pm ET
To enhance efficiency and rigor, NIH intends to modernize the approach to data and safety monitoring and is committed to engaging the public in development of an updated policy. Since the 1998 NIH Data and Safety Monitoring Policy was published, study designs and monitoring practices have evolved, creating the need for more efficient and flexible practices to monitor data for all clinical research. NIH plans to modernize the Data and Safety Monitoring Policy starting with gathering input from the public, experts in the field, and the research community.
NIH Videocast
https://videocast.nih.gov
Draft Agenda
Draft Agenda
Meeting Flyer
Meeting Flyer
All types of clinical research studies can – and should – have a plan for monitoring data and safety. These studies include a broad range of clinical research studies, such as observational studies, behavioral and social science research, implementation science, and clinical trials of drugs and devices.
- Data and safety monitoring plans identify the approach and procedures for monitoring the quality and scientific reliability of the data, and the safety of participants.
- Plans include procedures for evaluating and reporting on the data and safety of the study.
- Plans identify the appropriate level of monitoring for the study and describe how that monitoring will be conducted.
- Monitoring can range from the principal investigator only to including an independent monitor(s) or committee, like a Data and Safety Monitoring Board (DSMB).
NIH welcomes any comments on modernizing the Data and Safety Monitoring (DSM) Policy. We accept any comments, but we are specifically interested in hearing individual opinions on the following topics:
- Study characteristics that should be considered when evaluating what an appropriate monitoring approach, plan, or level of monitoring is for the study. For example, this could include the study design, types of outcomes, data privacy and security, US or global regulatory structure, number of sites, and quantity and types of data.
- Key components of an effective data and safety monitoring plan; considering data, safety, scientific integrity, protocol adherence, and study continuation.
- Types of research that should be covered under the modernized DSM policy. Key categories are 1) all clinical research (including clinical trials and non-clinical trials) and 2) all research involving humans, including identifiable private information or specimens (i.e., secondary research involving de-identified private information or biospecimens).
- Guidance, templates, or educational material that would help the research community 1) understand data and safety monitoring principles, 2) develop effective data and safety monitoring approaches and plans, and 3) implement data and safety monitoring rigorously and to the highest ethical standards.
Registration
Registration for this event is now closed.
Event Date:
04/27/2026
Time: 1:00 – 3:30 pm ET
NIH is undertaking a comprehensive policy development process that will require researchers and institutions to responsibly share summary level study results to research participants in plain language for all NIH-supported clinical research. This webinar, co-hosted by the Multi-Regional Clinical Trial Center of Brigham and Women’s Hospital and Harvard, is an opportunity for stakeholders to provide feedback to inform the development of that policy.
NIH Videocast
https://videocast.nih.gov
Draft Agenda
Draft Agenda
Meeting Materials
Introductory Slides
Lyric Jorgenson, PhD
Associate Director for Science Policy, National Institutes of Health
NIH encourages any interested individual to sign up to provide oral comments during the listening session. All comments offered at the listening session are welcome and will be considered. Feedback on the following topics is particularly encouraged.
What to include in summary level study results shared with participants. Specifically:
- Elements and information that should be expected to be included in summary level study results shared with participants
- Situations when not sharing summary level study results with participants may be justifiable
- Strategies for generating plain language summaries, including the use of AI tools
How to share summary level study results with participants. Specifically:
- Best practices for participant engagement to ensure that results are returned in meaningful ways and participants know what to expect
- Acceptable and preferred methods for sharing and receiving summary level results
- Potential costs related to generating and sharing summary level results
- Additional considerations related to ensuring results are returned responsibly
When to share summary level study results with participants. Specifically:
- Timing of sharing summary level study results (during or after the study)
Event Date:
04/27/2022
Time: 12pm to 3pm
NIH will hold a virtual meeting and listening session to engage stakeholders and gather feedback on the current U.S. Government oversight framework for research involving enhanced potential pandemic pathogens.
Specifically, NIH is interested in hearing from a wide range of stakeholders on the scope of the framework, strategies for minimizing potential biosafety and biosecurity risks, considerations for supporting international ePPP research and how to balance security with public transparency. This meeting and listening session will also help inform the deliberations and policy recommendations of the NSABB related to its current charge. Time will also be on the agenda for members of the public to provide comments at the meeting.
Webcast
https://videocast.nih.gov/watch=45230
Agenda
Meeting and Virtual Listening Session Agenda
Background Materials
Public Comments
Webcasts
Agenda
Meeting Minutes
Slides
Additional Materials
For accessibility assistance with these files, please contact: [email protected].